← boardnext 2027-09
UPB
Upstream Bio Inc.distress 3/10 · well-funded / low risk$6.48-2%today-80% from 52w high
Respiratory 1
Lead: Severe Asthma · est. market ~$22B (approx, global)
Revenue
pre-revenue
Liquidity
$295M
Runway
2.1 yrs
Shares 1y
+1%
Price & events
-79.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.7%
1D
-10.4%
1W
+2.5%
1M
-32.5%
3M
-78.4%
6M
-43.8%
1Y
—
2Y
—
5Y
-70.5%
All
Overview
- Market Cap
- $352.64M
- Volume
- 19.57K
- 52 Week Range
- $5.92 – $32.60
- Total Shares
- 54.42M
- Float Shares
- 40.62M
- Short %
- 11.63%
- % Held by Insiders
- 14.88%
- % Held by Institutions
- 88.32%
- RVOL
- 0.03x
Pipeline stages · 1 programs
Verekitug
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-09 Estimated 50% readout ~2027-10-16 | Phase 2 | Verekitug | Severe Asthma | — | active not recruiting |
| 2028-04 Estimated 50% readout ~2028-05-16 | Phase 2 | Verekitug | Chronic Obstructive Pulmonary Disease | — | active not recruiting |
| 2025-12-16 | Phase 2 | Verekitug (UPB-101) | Severe Asthma | 479 | completed |
| 2025-07-07 | Phase 2 | Verekitug (UPB-101) | Chronic Rhinosinusitis With Nasal Polyps | 81 | completed |
Catalyst news & presentations · 1
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $38 (+490% upside) · 8 analysts
- 2026-06-12JP MorganOverweight → Neutral
- 2026-06-03HC Wainwright & Co.Buy
- 2026-05-14MizuhoOutperform
- 2026-03-27Evercore ISI GroupOutperform → In-Line
- 2025-12-18MizuhoOutperform
- 2025-12-02LifeSci CapitalOutperform
Competitors — Severe Asthma
Recent news
- 2026-07-20Enterprise value to revenue forward of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
- 2026-07-16ETFs Investing in Upstream Bio, Inc. Stocks - TradingView
- 2026-07-14Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
- 2026-07-01Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Modest Stock Decline - Diluted EPS Report - dars.gov.et
- 2026-06-27Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Sentiment - Gross Profit Margin - dars.gov.et
- 2026-06-27Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Sentiment - EPS Estimate Trend - dars.gov.et
- 2026-06-26UPB Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-25Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage? - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.